ADMA Biologics (NASDAQ: ADMA) saw its stock price surge 5.06% in Wednesday's trading session, as investors showed optimism ahead of the company's anticipated third-quarter earnings report. The biopharmaceutical firm, which specializes in developing and commercializing plasma-derived biologics, is scheduled to release its financial results after market close.

Market analysts are projecting a positive outcome for ADMA Biologics this quarter. According to earnings estimates provided by FactSet Research Systems Inc., the company is expected to report earnings of $0.15 per share for Q3. This forecast suggests a significant improvement in the company's financial performance, potentially driving investor enthusiasm and contributing to the stock's upward movement.

The pre-earnings rally indicates that investors are betting on ADMA Biologics to meet or exceed these expectations. The company's focus on plasma-derived products, particularly in the immune deficiency market, has been gaining traction. If the actual results align with or surpass the projected figures, it could further validate the company's growth strategy and potentially lead to sustained positive sentiment among shareholders.